Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 20.45 as of 2026-10-06T19:23:13.519Z.
Consensus retrieved: 2026-10-06T14:46:48.918Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:23:13.519Z.
Quote observation: 2026-10-06T19:20:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f193908f80b4bef67825d748a40dd6188377eb54585c233fd38ba34bb0ad8150
Forward PE Ratio (20.45) = Dated Quote Price ($18.54) / Consensus Forward EPS ($0.91)
FORWARD PE RATIO
20.45
SECTOR MEDIAN · HEALTHCARE
19.87
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+2.92%
vs the sector median at left
Omeros Corporation
Market Cap
$1.34B
Forward PE Ratio
20.45
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Omeros Corporation (OMER) | $1.34B | 20.45 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.40B | 28.82 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.41B | N/A |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | N/A |
Trailing P/E
10.8
reported TTM EPS
Forward P/E
20.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.91 implies -47.1% EPS decline vs the reported trailing $1.72.
At the dated quote price of $18.54, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.91 | $0.73 – $1.10 | 2 | 20.4x |
| 2027-12-31 | $1.06 | $0.21 – $1.90 | 2 | 17.5x |
| 2028-12-31 | $1.61 | $0.83 – $2.10 | 3 | 11.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
